Noninfringement Defense Based on Prior Commercial Use Under 35 U.S.C. § 273 Must Be Timely and Expressly Pleaded

May 9, 2024

Reading Time : 2 min

The district court in a patent infringement case granted plaintiff’s ex parte request to strike defendant’s prior use defense under 35 U.S.C. § 273. Because defendant failed to plead the defense and did not raise it until just prior to the final pretrial conference, the court struck the defense as untimely.

Amended by the America Invents Act in 2011, Section 273 provides a noninfringement defense to a claim for patent infringement based on the defendant’s prior commercial use of the claimed product. This defense is separate and distinct from an invalidity defense based on prior public use under Section 102(a). And to rely on it, the defendant must introduce clear and convincing evidence that the defendant commercially used a product that meets the claim limitations prior to the effective filing date of the claims.

Here, after the court granted plaintiff’s motion for summary judgment of no invalidity, defendant sought to raise a defense under Section 273. In response, plaintiff filed an ex parte request to strike the defense as untimely. According to plaintiff, the first-time defendant had raised the defense was in its pretrial Memorandum of Contentions of Fact and Law. Defendant argued that it had pleaded facts consistent with a prior use defense. But the court struck the defense, holding that defendant had to actually plead a prior commercial use defense to infringement and could not merely rely on background facts consistent with the defense to establish that the defense had been timely raised. The court noted that the statutory language of Section 273(f), which requires a reasonable basis for asserting the defense, also suggests that the defense must be actually pleaded. 

Relatedly, the court granted-in-part plaintiff’s motion in limine seeking to exclude defendant’s arguments and evidence comparing its own products to prior art devices. Defendant argued that these comparisons were relevant to plaintiff’s infringement claims, defendant’s prior use defense to infringement and damages. Because the court struck defendant’s purported prior commercial use defense as untimely and concluded that the evidence was irrelevant to infringement, the court excluded defendant’s evidence and arguments suggesting that its own products practice the prior art. The court did, however, refrain from excluding defendant’s arguments and evidence for the narrow purpose of potentially rebutting plaintiff’s willful infringement arguments by showing that defendant had a good faith belief that the asserted patents were invalid. 

Practice Tip: Although some defendants may be hesitant to rely on Section 273, which requires clear and convincing evidence that the accused product meets the claim limitations, the defense may still be useful where, for example, infringement is not contested. But if a defendant wants to assert the prior commercial use defense, the defense should be raised expressly in the pleadings to avoid waiver. Alleging facts that are merely consistent with the defense will not be sufficient. 

Delta T LLC v. MacroAir Technologies, Inc., Case Nos. 5:20-cv-00728-GW-GJS, D.I. 399 (C.D. Cal. Apr. 19, 2024).

Share This Insight

Previous Entries

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

IP Newsflash

January 17, 2025

The District of Arizona recently held that a plaintiff’s failure to mark patented products during the time period that marking was required barred it from recovering all pre-notice damages, including for a period of time when there was no obligation to mark.

...

Read More

IP Newsflash

January 16, 2025

The Unified Patent Court (UPC) aims to provide expeditious decisions for its litigants. That means that there is a higher bar for obtaining extensions of time. As exemplified in BMW v. ITCiCo, the UPC’s reluctance to grant extensions can have serious consequences, including revocation of the patent.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.